Literature DB >> 23244241

Clinical profile, management, and outcome of retinoblastoma in singapore.

Fiona Pin Miao Lim1, Shui Yen Soh, Jayant Venkatramani Iyer, Ah Moy Tan, Handa Swati, Boon Long Quah.   

Abstract

PURPOSE: To analyze the clinical manifestations and treatment outcomes for patients with retinoblastoma in Singapore from 1997 to 2010.
METHODS: Medical records of 51 patients (67 eyes) diagnosed as having retinoblastoma were analyzed. Data on laterality, genetics, presentation, disease severity, treatment, and prognosis were collected.
RESULTS: The mean age of presentation was 25.7 ± 19.9 months. Sixteen (31.4%) of the patients had bilateral disease, of whom 2 had an associated pineal tumor. Leukocoria was the most common sign. Two had metastasis at diagnosis. Only 3 patients (5.9%) had a family history. Using the International Intraocular Retinoblastoma Classification, 6.0% were Group A, 6.0% were Group B, 3.0% were Group C, 38.8% were Group D, and 49.2% were Group E. Chemotherapy and focal therapy were administered for 4 of 35 (12.9%) patients with unilateral retinoblastoma (50% had successful globe preservation) and 13 of 16 (81.3%) patients with bilateral retinoblastoma (42.3% had successful globe preservation). Overall, globe preservation was achieved in 100% of Groups A, B, and C, and 23.1% of Group D cases. The 5-year survival rate overall, for unilateral retinoblastoma, and for bilateral retinoblastoma was 91%, 97%, and 76% respectively.
CONCLUSION: The overall 5-year survival rate is comparable to international data in most developed countries. However, most patients presented with advanced disease, making the rate of globe preservation lower than in some developed countries. Better education of the public and healthcare professionals may increase awareness and enable early detection of the disease. Copyright 2013, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23244241     DOI: 10.3928/01913913-20121211-01

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  11 in total

1.  An international survey of classification and treatment choices for group D retinoblastoma.

Authors:  Christina Scelfo; Jasmine H Francis; Vikas Khetan; Thomas Jenkins; Brian Marr; David H Abramson; Carol L Shields; Jacob Pe'er; Francis Munier; Jesse Berry; J William Harbour; Andrey Yarovoy; Evandro Lucena; Timothy G Murray; Pooja Bhagia; Evelyn Paysse; Samuray Tuncer; Guillermo L Chantada; Annette C Moll; Tatiana Ushakova; David A Plager; Islamov Ziyovuddin; Carlos A Leal; Miguel A Materin; Xun-Da Ji; Jose W Cursino; Rodrigo Polania; Hayyam Kiratli; Charlotta All-Ericsson; Rejin Kebudi; Santosh G Honavar; Vicktoria Vishnevskia-Dai; Sidnel Epelman; Anthony B Daniels; Jeanie D Ling; Fousseyni Traore; Marco A Ramirez-Ortiz
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

2.  Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma.

Authors:  David H Abramson; Armida W M Fabius; Jasmine H Francis; Brian P Marr; Ira J Dunkel; Scott E Brodie; Anna Escuder; Y Pierre Gobin
Journal:  Ophthalmic Genet       Date:  2017-01-17       Impact factor: 1.803

3.  Clinical Presentations and Outcomes of Retinoblastoma Patients in relation to the Advent of New Multimodal Treatments: A 12-Year Report from Single Tertiary Referral Institute in Thailand.

Authors:  Duangnate Rojanaporn; Taweevat Attaseth; Wimwipa Dieosuthichat; Kitikul Leelawongs; Samart Pakakasama; Usanarat Anurathapan; Ekachat Chanthanaphak; Sirintara Singhara Na Ayudhaya; Rangsima Aroonroch; Suradej Hongeng
Journal:  J Ophthalmol       Date:  2020-09-10       Impact factor: 1.909

Review 4.  Intravenous Chemotherapy for Retinoblastoma in the Era of Intravitreal Chemotherapy: A Systematic Review.

Authors:  Vishal Raval; Randy Christopher Bowen; Hansell Soto; Arun Singh
Journal:  Ocul Oncol Pathol       Date:  2020-12-16

5.  Globe salvage treatment in group D and group E retinoblastoma.

Authors:  Ahmad Khaqan Hussain; Rachwani Anil Rahul; Rocha de Lossada Carlos; Zamorano Martín Francisco; García Lorente María; Pennisi Flavia; Bonzano Chiara; Borroni Davide
Journal:  Rom J Ophthalmol       Date:  2021 Jan-Mar

6.  Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma.

Authors:  David H Abramson; Anthony B Daniels; Brian P Marr; Jasmine H Francis; Scott E Brodie; Ira J Dunkel; Y Pierre Gobin
Journal:  PLoS One       Date:  2016-01-12       Impact factor: 3.240

7.  Epidemiological Characteristics of Retinoblastoma in Children Attending Almouassat University Hospital, Damascus, Syria, 2012-2016

Authors:  Ahmad Al Hasan; Rashad Murad; Khaldoun Zaid; Jourjous Al Daoud; Khaled Zaid
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

8.  Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis.

Authors:  Huimin Hu; Weiling Zhang; Yizhuo Wang; Dongsheng Huang; Jitong Shi; Bin Li; Yi Zhang; Yan Zhou
Journal:  BMC Ophthalmol       Date:  2018-04-23       Impact factor: 2.209

9.  Retinoblastoma: A Sixteen-Year Review of the Presentation, Treatment, and Outcome from a Tertiary Care Institute in Northern India.

Authors:  Usha Singh; Deeksha Katoch; Savleen Kaur; Mangat Ram Dogra; Deepak Bansal; Rakesh Kapoor
Journal:  Ocul Oncol Pathol       Date:  2017-07-05

10.  Mutation spectrum of RB1 mutations in retinoblastoma cases from Singapore with implications for genetic management and counselling.

Authors:  Swati Tomar; Raman Sethi; Gangadhara Sundar; Thuan Chong Quah; Boon Long Quah; Poh San Lai
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.